Substance / Medication

Atropine

Overview

Active Ingredient
atropine
RxNorm CUI
1223

Indications

Atropine is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity as well as organophosphorus or carbamate insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds).

Labeler: Rafa Laboratories, Ltd.Updated: 2026-02-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
3
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children's populations.
Navarra Pierluigi, Buzzonetti Luca, Amico Valentina et al. · Front Pharmacol · 2025
PMID: 40474980Meta-AnalysisFull text (PMC)
Impact of atropine on changes in choroidal thickness in children with myopia: a meta-analysis of randomized controlled trials.
Liu Li Ping, Tang Yun, Zhang Jun Na et al. · Front Med (Lausanne) · 2025
PMID: 41127393Meta-AnalysisFull text (PMC)
Effects of atropine on choroidal thickness in myopic children: a meta-analysis.
Yang Yaqi, Wei Lijuan, Wang Bo et al. · Front Pharmacol · 2024
PMID: 39498339Meta-AnalysisFull text (PMC)
Myopia progression after cessation of atropine in children: a systematic review and meta-analysis.
Lee Ssu-Hsien, Tsai Ping-Chiao, Chiu Yu-Chieh et al. · Front Pharmacol · 2024
PMID: 38318144Meta-AnalysisFull text (PMC)
Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis.
Yellepeddi Venkata K, Race Jonathan A, McFarland Mary M et al. · Int J Clin Pharmacol Ther · 2024
PMID: 38577753Meta-Analysis
Effects of atropine eyedrops at ten different concentrations for myopia control in children: A systematic review on meta-analysis.
Wang Jin-Da, Liu Mei-Rui, Chen Chang-Xi et al. · Eur J Ophthalmol · 2024
PMID: 38377951Meta-Analysis
Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis.
Hou Peixian, Wu Dawen, Nie Yan et al. · Front Pharmacol · 2023
PMID: 37767401Meta-AnalysisFull text (PMC)
Incidence of Adverse Events Induced by Atropine in Myopic Children: A Meta-Analysis.
Sun Hong, Bu Fengjiao, Xin Xiu et al. · J Clin Pharmacol · 2023
PMID: 37492894Meta-Analysis
Analysis of the reports of low-concentration atropine in controlling myopia in children.
Zhang M, Qiu W, An M et al. · J Fr Ophtalmol · 2023
PMID: 36797093Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Atropine (substance)
SNOMED CT
372832002
UMLS CUI
C0004259
RxNorm CUI
1223
Labeler
Rafa Laboratories, Ltd.

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.